
Starting With the Non-Negotiables: Selecting Adjunctive Therapy in MDD
Five atypical antipsychotics now carry FDA approval as adjunctive MDD treatment, and Erin Crown walks through how weight, metabolic risk, and anxious depression shape her choice among them.
Episodes in this series

In "Starting With the Non-Negotiables: Selecting Adjunctive Therapy in MDD," Erin Crown, MHS, PA-C, CAQ-Psychiatry compares the adjunctive options available today and how patient profile drives her selection.
Erin Crown names the five atypical antipsychotics with FDA approval as adjunctive treatment for adults with major depressive disorder: quetiapine, aripiprazole, brexpiprazole, cariprazine, and the newest addition, lumateperone. Choosing among them, she says, requires taking in the whole patient. She considers current BMI and weight gain risk, since some agents carry a higher likelihood of adverse weight gain than others, along with existing metabolic issues such as hyperlipidemia, elevated glucose, prediabetes, or type 2 diabetes. Tardive dyskinesia risk factors, discussed in an earlier episode, also weigh into the decision, since each option varies slightly in that risk. Erin Crown also assesses whether a patient shows anxious depression, a phenotype she describes as harder to treat and slower to respond, alongside anhedonia and cognitive symptoms.
For a patient unwilling to risk weight gain, Erin Crown says lumateperone is often the direction she takes, since its clinical trials showed no meaningful weight changes compared with other adjunctive options. She also favors it for patients with anhedonia or anxious depression, marked by poor sleep, worry, restlessness, and cognitive symptoms. Roughly 40 percent of participants in lumateperone's trials had anxious depression, and improvement generally appeared within one to two weeks, slightly longer for that anxious subgroup. Erin Crown highlights a favorable tolerability profile: no meaningful changes in weight, prolactin, or metabolic markers, and no meaningful increase in involuntary motor movements such as tardive dyskinesia, parkinsonism, or akathisia. For a patient who isn't managing basic self-care, she says she may lean toward a different adjunctive option instead. Erin Crown starts every adjunctive conversation by asking patients what they consider non-negotiable, then works backward from that answer toward the right agent for that person.
One practical takeaway she would want colleagues to carry into their own practice starts with relationship. She urges clinicians to build real rapport with patients, to have genuine conversation, and to do the deeper, probing follow-up when a patient is volunteering less information than usual. From there, she returns to what has anchored the entire conversation: keeping remission, not simply response, as the central treatment goal. Erin Crown acknowledges that clinicians will not always reach remission and will sometimes be disappointed by a patient's course, but argues that settling for less is too risky, both for patients and for the clinicians treating them, given the relapse, functional, and safety consequences of leaving symptoms unresolved.
Erin Crown also points to a pattern she finds notable: the treatments currently showing the strongest remission data in major depressive disorder are not another SSRI, SNRI, NDRI, or tricyclic working through familiar mechanisms. Instead, they act directly or indirectly on glutamate, the most excitatory neurotransmitter in the central nervous system. She encourages colleagues to build a working understanding of glutamate's role across disease states, including MDD, and of how regulating its dysregulation supports patients on the path toward wellness.
Up next, in "Rapid-Acting Antidepressants and the Psychedelics Debate," Dr. Citrome and Dr. Harding close the series with the newest rapid-acting options, from glutamatergic agents to psychedelics.
Related to this article








